On January 9, 2017, AbbVie, a world-renowned research biopharmaceutical company, Irish Genomics Medicine (GMI), a new life sciences company, and Mingmao (Shanghai) Biotechnology, the world's leading genomics information and precision medicine company. WuXi NextCODE (hereafter referred to as “Ming Biotechâ€) announced the establishment of a long-term strategic alliance to conduct population genomics research across Ireland to develop new treatment options for a range of serious and complex diseases. The Alliance will engage in a 15-year partnership focused on cancer, neurological and immune system chronic diseases affecting hundreds of thousands of people in Ireland and hundreds of millions of people around the world. The Alliance will rely on Alberta’s existing resources in Ireland to identify and identify new drug targets by sequencing the 4,500 volunteers across Ireland, providing better clinical outcomes for a variety of complex diseases. Treatment programs. Abbott will use the research database of the Irish Genomics Medicine Company to establish a new molecular biology method for the development of therapeutic drugs and accompanying diagnostic reagents. To date, Abbott has more than 600 employees in Ireland and has invested more than $130 million since 2013. Aberdeen is a world-renowned research biopharmaceutical company that was split from Abbott in 2013. Biopharmaceuticals have always been Abbott’s expertise, and Abbott’s skills have played an important role in the league. The focus of this collaborative research will focus on Abbie's main research directions, including cancer, nerves and immunity. If the body of Abbie's alliance, then the Irish genome medicine is like the engine of the alliance. The company is a cutting-edge life sciences research company in Ireland that aims to clarify the relationship between heredity, health and disease by promoting genome research in large-scale populations across Ireland, and is working to create a database of high-performance diseases. At the same time, the company has worked extensively with clinicians, patients, academic researchers, biotechnology and pharmaceutical companies to promote innovation in life sciences in Ireland. This time, Abbott will use the research database of the Irish Genomics Medicine Company to establish a new molecular biology method for the development of therapeutic drugs and accompanying diagnostic reagents. With the body and engine, WuXi NextCODE joined the alliance to add a security system to the alliance. WuXi NextCODE is a global leader in precision medicine with the integration of the WuXi PharmaTech Genomics Center and the leading medical data analysis leader, NextCODE Health. It is committed to using precision medical big data to improve human health. Based on the world's leading comprehensive genomics research platform, Mingma Bio will build a secure, scalable genome-wide sequence and medical data database for the Alliance to deepen understanding of new diseases. Tetanus Vaccine,Hepatitis B Vaccine For Adults,Tetanus Booster,Td Vaccine FOSHAN PHARMA CO., LTD. , https://www.foshanpharma.com